Data for: Therapy-related acute myeloid leukemia developing 14 years after allogeneic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.

Published: 18-07-2018| Version 1 | DOI: 10.17632/hx4nwr8yyd.1
Iván Martín,
Felipe J Chaves,
Rosario Abellán,
Francisca García,
Mar Tormo,
Carlos Solano,
Juan-Carlos Hernandez-Boluda,
Loles Olivares ,
Eva Villamón,
Fernando Domingo,
Blanca Navarro,
Marisa Calabuig,
Paula Amat,
Alicia Serrano


Supplementary (DOCX 2.34MB): Materials and methods. Fig. S1. TP53 mutation found in the lung carcinoma cells taken from the patient in 2012. Fig. S2. Karyotype illustrating the metaphases of the 2015 therapy-related myelodysplastic syndrome cells. Fig. S3. Paint of chromosome 15 (green) by fluorescent in situ hybridization. Fig. S4. Analysis of the chimerism (Mentype® Chimera® software, Biotype) at 2015 therapy-related acute myeloid leukemia diagnosis. Fig. S5. IDH1, DNMT3A and NPM1 mutations found at the time of the acute myeloid leukemia diagnosis in 2001. Fig. S6. DNMT3A and TP53 mutations found at the time of the therapy-related acute myeloid leukemia diagnosis in 2015. Fig. S7. Standard curve for the ASO-qPCR. Fig. S8. Sensitivity assay for quantitative ASO-qPCR.